Happify unveils the first digital therapeutics to treat both MDD and GAD
Designed as an adjunct to care for MDD and GAD, Ensemble must be prescribed by a clinician to treat these disorders.
Digital therapeutics company Pear Therapeutics to go public in a $1.6B SPAC deal
The deal provides additional investment to capitalize on Pear's position by investing in the commercialization of its three FDA-authorized products.
MindMaze scores new partners, enters new markets
Bringing the future of brain repair for stroke, Parkinson's, and other neurological conditions to patients in Latin America, Europe and Middle East.
Pear Therapeutics licenses multiple technologies to bolster its PDT platform
The company has expanded its platform with digital biomarkers, machine learning algorithms and sensor-based technologies.
Pear Therapeutics launches Somryst for chronic insomnia
Somryst is the only FDA-authorized prescription digital therapeutic for the treatment of chronic insomnia.
10 promising digital therapeutics
Today, we are witnessing an upsurge in health concerns. More than half of the population has diabetes, fluctuating blood pressure, and mental health issues....
Orexo launches digital therapeutics using Accenture’s INTIENT platform
The solution, called vorvida, is launching for patients in the United States dealing with problematic alcohol use.
Pear Therapeutics publishes real-world utilization data for reSET-O
Near-term reductions in medical costs after prescription of reSET-O exceeded the amount needed to offset the cost of the product.
Juniper: There will be 1.4B digital therapeutics and wellness app users by 2025
The growth comes after regulators responded to COVID-19 by loosening rules that had previously hindered the work of digital therapeutics developers.
PreferredOne taps Pear to become the first health plan to cover digital therapeutics
PreferredOne will provide broad patient access and reimbursement for reSET and reSET-O for people with substance use disorder and opioid use disorder.